Compare Linde PLC (LIN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Nuwellis Inc — how do they compare? Linde PLC trades at $504.74 (market cap $236.74B), while Nuwellis Inc trades at $2.85 (market cap $1.09M). The key difference: Linde PLC is far larger — about 217192.7× Nuwellis Inc's market cap, and Linde PLC pays a 1.25% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| LIN | NUWE | |
|---|---|---|
Market Cap | $236.74B | $1.09M |
Sector | Basic Materials | Technology |
52-Week High | $546.64 | $527.46 |
52-Week Low | $389.38 | $2.80 |
Enterprise Value | $259.10B | -$722.58K |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $513.07, down 1.47% today, with strong fundamentals including 20.44% net income margin and consistent earnings beats. Technical indicators show a bearish trend with support at $509 and resistance at $520. The company maintains robust cash flow from operations of $10.35B and has raised dividends, reflecting financial health.
Outlook remains positive with 89% analyst buy ratings and a $564.80 price target, though valuation ratios are elevated. Risks include rising debt-to-asset ratio (31.63% in 2025) and potential macroeconomic pressures. The stock offers growth potential but requires monitoring of leverage and market conditions.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
